Merck & Co., Inc. (NYSE:MRK) announced Monday that it has entered into a multi-year collaboration agreement with NGM Biopharmaceuticals Inc., a privately held biotechnology company, to research, develop, as well as commercialize innovative biologic therapies ranging across a wide array of therapeutics.
Posted by Leo E. Strine, Jr., Delaware Supreme Court and Harvard Law School, on Thursday, November 5, 2015 Editor's Note: Leo E. Strine, Jr. is Chief Justice of the Delaware Supreme Court, the Austin Wakeman Scott Lecturer on Law and a Senior Fellow of the Harvard Law School Program on Corporate Governance.
Merck & Co., Inc. (NYSE:MRK), the second-largest US drug maker, has announced an agreement with the Medicines Patent Pool (MPP) for its HIV drug, raltegravir, in its efforts to expedite the process of developing low-priced pediatric formulations for developing countries.
Editor’s Note: Richard J. Sandler is a partner at Davis Polk & Wardwell LLP and co-head of the firm’s global corporate governance group. This post is based on a Davis Polk client memorandum.
Amid the recent uptick in U.S. IPO transactions to levels not seen since the heady days of 1999 and 2000, Davis Polk’s pipeline of deals remains robust, leading us to believe that strength in the U.S.
Posted by Martin Lipton, Wachtell, Lipton, Rosen & Katz, on Friday, October 30, 2015 Editor's Note: Martin Lipton is a founding partner of Wachtell, Lipton, Rosen & Katz, specializing in mergers and acquisitions and matters affecting corporate policy and strategy. This post is based on a Wachtell Lipton memorandum by Mr. Lipton and Sabastian V. Niles. Mr.
Editor's Note: The following post comes to us from Lili Dai of the College of Business and Economics at Australian National University; Jerry Parwada and Bohui Zhang, both of the Finance Area at UNSW Australia.
That the medi
Merck & Co., Inc. (NYSE:MRK) ended up paying $8.4 billion to acquire Cubist Pharmaceuticals Inc (NASDAQ:CBST), a 37% premium over Cubist’s closing stock price of $74.36 Friday; however, by Monday morning, this amount looked at least $2 billion too high as Cubist lost a key patent-infringement case pertaining to its blockbuster drug, Cubicin.
Editor's Note: The following post comes to us from Benjamin Hermalin, Professor of Finance at the University of California, Berkeley; and Michael Weisbach, Professor of Finance at Ohio State University.
The central focus of research in corporate governance has historically been on the problems of controlling managers’ actions.
Editor’s Note: Andrew R. Brownstein is a partner in the Corporate Department at Wachtell, Lipton, Rosen & Katz. This post is based on a Wachtell Lipton firm memorandum by Mr. Brownstein, Adam O. Emmerich, David A. Katz, Trevor S.
Chemistfrog submits:Ariad Pharmaceuticals (NASDAQ: ARIA) captured Merck’s (NYSE: MRK) attention enough with its cancer drug, ridaforolimus, in July 2007 to forge a partnership to help Ariad through several clinical trials for multiple cancer indications.